



FDA ADVISORY  
No. **2021-2208**

**26 AUG 2021**

**TO : ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

**SUBJECT : Public Health Warning Against the Purchase and Use of the following Verified Counterfeit Drug Products:**

1. Phenylephrine HCl / Chlorphenamine Maleate / Paracetamol (Neozep® Forte) 10 mg/2 mg/500 mg Tablet
2. Dextromethophan HBr / Phenylpropanolamine HCl / Paracetamol (Tuseran® Forte) 15mg/25mg/325mg Capsule

The Food and Drug Administration (FDA) advises the public against the purchase and use of the following verified counterfeit drug products:

**AUTHENTIC**



**COUNTERFEIT**



**Counterfeit** – Security mark, print color and appearance of the box are different with the standard features of the registered drug product

Figure 1. Comparison between the secondary packaging (box) of the Authentic and Verified Counterfeit Phenylephrine HCl/Chlorphenamine Maleate / Paracetamol (Neozep® Forte) 10 mg/2 mg/500 mg Tablet (Lot no. 13127758 Expiry date Mar 2022)



## AUTHENTIC



## COUNTERFEIT



**Counterfeit** – Logo, security mark, knurling, print color and appearance are different with the features of the registered product

Figure 2. Comparison between the Primary packaging (Blister pack) of the Authentic and Verified Counterfeit Phenylephrine HCl / Chlorphenamine Maleate / Paracetamol (Neozep® Forte) 10 mg/2 mg/500 mg Tablet (Lot no. 13127758 Expiry date Mar 2022)



**AUTHENTIC**



**COUNTERFEIT**



**Counterfeit** – Logo, security mark, knurling, print color and appearance are different with the features of the registered product

Figure 2. Comparison between the Primary Packaging of the Authentic and Verified Counterfeit Dextromethophan HBr/Phenylpropanolamine HCl/ Paracetamol (Tuseran<sup>®</sup> Forte) 15mg/25mg/325mg Capsule (Lot no. U004923 Expiry date Jan 2022)

All healthcare professionals and the general public are hereby warned as to the availability of these counterfeit drug products in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug products only from FDA-licensed establishments. Always check if a product is registered with the FDA by using the FDA Verification Portal feature accessible at <http://verification.fda.gov.ph>.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit products with the abovementioned features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug products will be penalized.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at [info@fda.gov.ph](mailto:info@fda.gov.ph). To report continuous sale or distribution of unregistered health products, kindly e-mail us via [report@fda.gov.ph](mailto:report@fda.gov.ph), or through the online reporting facility, **eReport**, at [www.fda.gov.ph/ereport](http://www.fda.gov.ph/ereport). You may also call the Center for Drug Regulation and Research at telephone number **(02) 8809-5596**. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH> and fill out all the required fields.

Dissemination of the information to all concerned is requested.

  
**ROLANDO ENRIQUE D. DOMINGO, MD**  
Director General

DTN:



20210819134327